DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

ESR, CRP and inflammatory markers

Essential points for quick revision.

!
Escalate

Do not use a normal ESR or CRP to defer assessment of suspected septic arthritis, giant-cell arteritis with visual symptoms, spinal infection, rapidly progressive vasculitis or another organ-threatening presentation. Clinical urgency and definitive investigation take precedence over a screening marker.

Synopsis

Interpret ESR, CRP and related inflammatory markers as context-dependent trends, recognising discordance, non-rheumatic causes and the conditions in which a normal result cannot safely close the diagnosis.

  • CRP is a hepatic acute-phase protein that changes relatively quickly; ESR is an indirect sedimentation measure affected by fibrinogen, immunoglobulins, red-cell characteristics, age and pregnancy.
  • Neither test is specific for rheumatic disease: infection, cancer, trauma, tissue injury and obesity can raise inflammatory markers.
  • Normal markers do not exclude rheumatoid arthritis, axial spondyloarthritis, giant-cell arteritis, infection or connective-tissue disease when the phenotype remains convincing.

Key red flags

Acute CRP-dominant rise

A rapid CRP increase with systemic illness supports an acute inflammatory or infectious process and should be interpreted alongside cultures, imaging and organ function.

Investigation priorities

01
C-reactive proteinFirst step

Quantify a rapidly responsive acute-phase signal and follow a defined inflammatory trajectory.

Management branches

Dangerous phenotypeAct on the syndrome, not the marker

Septic joint, threatened vision, systemic vasculitis or spinal infection remains clinically plausible regardless of ESR or CRP.

  1. Perform urgent clinical and organ assessment, obtain the definitive samples or imaging and involve the responsible specialist without waiting for repeat markers.
  2. Begin time-critical treatment according to the relevant pathway when delay risks joint, vision, neurological or organ loss.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom